Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 18/20 | 0.49 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4270150 | 0.96 | F10 (0.50) | F10KLKB1NPC1RAB9ATSHR | |
| Hydrochloric Acid SCHEMBL4272493 | 0.95 | F10 (0.49) | F10KLKB1NPC1RAB9ATSHR | |
| SCHEMBL4270815 | 0.91 | F10 (0.57) | F10NPC1RAB9AKDM4E | |
| Hydrochloric Acid SCHEMBL4270894 | 0.90 | F10 (0.56) | F10NPC1RAB9AKDM4E | |
| SCHEMBL4269686 | 0.90 | F10 (0.54) | F10NPC1RAB9AKDM4E | |
| Hydrochloric Acid SCHEMBL4277221 | 0.89 | F10 (0.53) | F10NPC1RAB9AKDM4E | |
| SCHEMBL4277306 | 0.88 | F10 (0.51) | F10NPC1RAB9AKDM4E | |
| SCHEMBL4274122 | 0.86 | F10 (0.47) | F10NPC1RAB9AKDM4E | |
| SCHEMBL4277208 | 0.85 | F10 (0.46) | F10NPC1RAB9AKDM4E | |
| SCHEMBL4274332 | 0.85 | TRPV4 (0.51) | F10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7615568-B2 | 3-[2-(cis-4-aminocyclohexyloxy)-4-methylsulfonylbenzoyl-amino]-N-(5-chloropyridin-2-yl)pyridine-2-carboxamide,; anticoagulant; platelet glycoprotein receptor antagonist; thrombosis; orally; acylation of amino-pyridine by (methylthio)benzoic acid followed by oxidation, alkylation, carbonylation | ELI LILLY AND COMPANY (US) | 2009-11-10 | — | — | US | disclosed |
| US-20080108594-A1 | Antithrombotic Ethers | ELI LILLY AND COMPANY (US) | 2008-05-08 | — | — | US | disclosed |
| EP-1644334-B1 | ANTITHROMBOTIC ETHERS | LILLY CO ELI (US) | 2008-01-02 | — | — | EP | disclosed |
| EP-1644334-A1 | ANTITHROMBOTIC ETHERS | Eli Lilly and Company (US) | 2006-04-12 | — | — | EP | disclosed |
| WO-2004108677-A1 | ANTITHROMBOTIC ETHERS | ELI LILLY AND COMPANY (US) | 2004-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080108594-A1 | Antithrombotic Ethers | F11, SERPINC1, F2 | F10 16/4885KLKB1 310/4885NPC1 1622/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.